DE69309685T2 - Zweikomponenten-Fibrinkleber zur Verbesserung von in-Vitro Befruchtung - Google Patents
Zweikomponenten-Fibrinkleber zur Verbesserung von in-Vitro BefruchtungInfo
- Publication number
- DE69309685T2 DE69309685T2 DE69309685T DE69309685T DE69309685T2 DE 69309685 T2 DE69309685 T2 DE 69309685T2 DE 69309685 T DE69309685 T DE 69309685T DE 69309685 T DE69309685 T DE 69309685T DE 69309685 T2 DE69309685 T2 DE 69309685T2
- Authority
- DE
- Germany
- Prior art keywords
- component
- composition according
- fibrinogen
- fibrin
- components
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 title claims abstract description 22
- 230000004720 fertilization Effects 0.000 title claims description 11
- 238000000338 in vitro Methods 0.000 title claims description 11
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 20
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 20
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 20
- 108091005804 Peptidases Proteins 0.000 claims abstract description 8
- 238000012258 culturing Methods 0.000 claims abstract description 8
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract description 7
- 102000035195 Peptidases Human genes 0.000 claims abstract description 7
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims abstract description 7
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims abstract description 7
- 108010073385 Fibrin Proteins 0.000 claims abstract description 6
- 102000009123 Fibrin Human genes 0.000 claims abstract description 6
- 210000002308 embryonic cell Anatomy 0.000 claims abstract description 6
- 229950003499 fibrin Drugs 0.000 claims abstract description 6
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 4
- 229920000642 polymer Polymers 0.000 claims abstract description 3
- 210000001161 mammalian embryo Anatomy 0.000 claims description 17
- 108090000190 Thrombin Proteins 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 229960004072 thrombin Drugs 0.000 claims description 11
- 210000004291 uterus Anatomy 0.000 claims description 11
- 108010039627 Aprotinin Proteins 0.000 claims description 10
- 229960004405 aprotinin Drugs 0.000 claims description 9
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 8
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 235000002639 sodium chloride Nutrition 0.000 claims description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 6
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 108010027612 Batroxobin Proteins 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 235000011148 calcium chloride Nutrition 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 4
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 4
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 4
- 229960003531 phenolsulfonphthalein Drugs 0.000 claims description 4
- 235000011164 potassium chloride Nutrition 0.000 claims description 4
- 239000001103 potassium chloride Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 3
- 229930182566 Gentamicin Natural products 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 229940107700 pyruvic acid Drugs 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000003998 snake venom Substances 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims description 2
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 claims description 2
- 241000271897 Viperidae Species 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 2
- 239000002435 venom Substances 0.000 claims description 2
- 231100000611 venom Toxicity 0.000 claims description 2
- 210000001048 venom Anatomy 0.000 claims description 2
- 229960002210 batroxobin Drugs 0.000 claims 1
- 238000009395 breeding Methods 0.000 claims 1
- 230000001488 breeding effect Effects 0.000 claims 1
- 244000144972 livestock Species 0.000 claims 1
- 239000003357 wound healing promoting agent Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 abstract description 4
- 241000124008 Mammalia Species 0.000 abstract description 3
- 238000002513 implantation Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 5
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000001612 chondrocyte Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 108010071289 Factor XIII Proteins 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 3
- 229940012444 factor xiii Drugs 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 3
- 229960000401 tranexamic acid Drugs 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 230000032692 embryo implantation Effects 0.000 description 2
- 208000002854 epidermolysis bullosa simplex superficialis Diseases 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000003106 tissue adhesive Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- JWICNZAGYSIBAR-LEEGLKINSA-N (4s)-4-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-5-[[2-[[(2s)-3-carboxy-1-[[(2s)-1-[[1-[[(2s)-1-[[(2s)-4-carboxy-1-[[2-[[2-[[2-[[(2s)-1-[[(1s)-1-carboxy-4-(diaminomethylideneamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)C(CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)N)CC1=CC=CC=C1 JWICNZAGYSIBAR-LEEGLKINSA-N 0.000 description 1
- 101800000974 Fibrinopeptide A Proteins 0.000 description 1
- 102400000525 Fibrinopeptide A Human genes 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000535 fibrinogen concentrate Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 230000002727 hyperosmolar Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/225—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP92112295 | 1992-07-18 | ||
EP93105298 | 1993-03-30 | ||
PCT/EP1993/001797 WO1994002182A1 (fr) | 1992-07-18 | 1993-07-09 | Composition de colle fibrine a deux composants servant a ameliorer la fertilisation in vitro |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69309685D1 DE69309685D1 (de) | 1997-05-15 |
DE69309685T2 true DE69309685T2 (de) | 1997-10-16 |
Family
ID=26131003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69309685T Revoked DE69309685T2 (de) | 1992-07-18 | 1993-07-09 | Zweikomponenten-Fibrinkleber zur Verbesserung von in-Vitro Befruchtung |
Country Status (12)
Country | Link |
---|---|
JP (1) | JPH08502035A (fr) |
KR (1) | KR950702434A (fr) |
AT (1) | ATE151295T1 (fr) |
AU (1) | AU4566893A (fr) |
CA (1) | CA2140427A1 (fr) |
CZ (1) | CZ5495A3 (fr) |
DE (1) | DE69309685T2 (fr) |
FI (1) | FI950194A0 (fr) |
HU (1) | HUT71873A (fr) |
IL (1) | IL106293A0 (fr) |
SK (1) | SK5095A3 (fr) |
WO (1) | WO1994002182A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0691858B1 (fr) * | 1993-03-30 | 1999-12-15 | Omrix Biopharmaceuticals S.A. | Colle fibrine a deux constituants |
US5411885A (en) * | 1993-12-17 | 1995-05-02 | New York Blood Center, Inc. | Methods for tissue embedding and tissue culturing |
AU3145795A (en) * | 1994-07-26 | 1996-02-22 | Children's Medical Center Corporation | Fibrin-cell suspension for construction of new tissue |
DE69629010T2 (de) * | 1995-01-16 | 2004-04-15 | Baxter International Inc., Deerfield | Selbsttragende flächengebilde aus vernetztem fibrin zur hemmung von postoperativen adhäsionen |
WO1999025782A2 (fr) * | 1997-11-17 | 1999-05-27 | Haemacure Corporation | Agents de scellement ou adhesifs comprenant un materiau derive d'acide hyaluronique |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT369990B (de) * | 1981-07-28 | 1983-02-25 | Immuno Ag | Verfahren zur herstellung eines gewebeklebstoffes |
US4904259A (en) * | 1988-04-29 | 1990-02-27 | Samuel Itay | Compositions and methods for repair of cartilage and bone |
CH681693A5 (fr) * | 1991-02-28 | 1993-05-14 | Pentapharm Ag | |
SE9101853D0 (sv) * | 1991-06-17 | 1991-06-17 | Jonas Wadstroem | Improved tissue ashesive |
-
1993
- 1993-07-09 CA CA002140427A patent/CA2140427A1/fr not_active Abandoned
- 1993-07-09 KR KR1019950700191A patent/KR950702434A/ko not_active Application Discontinuation
- 1993-07-09 CZ CZ9554A patent/CZ5495A3/cs unknown
- 1993-07-09 HU HU9500141A patent/HUT71873A/hu unknown
- 1993-07-09 IL IL93106293A patent/IL106293A0/xx unknown
- 1993-07-09 AU AU45668/93A patent/AU4566893A/en not_active Abandoned
- 1993-07-09 AT AT93915861T patent/ATE151295T1/de active
- 1993-07-09 WO PCT/EP1993/001797 patent/WO1994002182A1/fr not_active Application Discontinuation
- 1993-07-09 DE DE69309685T patent/DE69309685T2/de not_active Revoked
- 1993-07-09 SK SK50-95A patent/SK5095A3/sk unknown
- 1993-07-09 JP JP6503912A patent/JPH08502035A/ja not_active Ceased
-
1995
- 1995-01-17 FI FI950194A patent/FI950194A0/fi unknown
Also Published As
Publication number | Publication date |
---|---|
ATE151295T1 (de) | 1997-04-15 |
HU9500141D0 (en) | 1995-03-28 |
AU4566893A (en) | 1994-02-14 |
DE69309685D1 (de) | 1997-05-15 |
IL106293A0 (en) | 1993-11-15 |
JPH08502035A (ja) | 1996-03-05 |
HUT71873A (en) | 1996-02-28 |
FI950194A (fi) | 1995-01-17 |
FI950194A0 (fi) | 1995-01-17 |
KR950702434A (ko) | 1995-07-29 |
CZ5495A3 (en) | 1995-06-14 |
CA2140427A1 (fr) | 1994-02-03 |
WO1994002182A1 (fr) | 1994-02-03 |
SK5095A3 (en) | 1995-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69333286T2 (de) | Eine thrombin-blutfraktion zur verwendung in einem medizinischen verfahren | |
EP0253198B1 (fr) | Colle pour tissu à un composant et son procédé de fabrication | |
DE69419324T2 (de) | Verfahren zur herstellung eines fibrinogen,faktor xiii und fibronectin enthaltenden biologischen klebstoffes | |
DE69422165T2 (de) | Zweikomponenten-fibrinkleber | |
DE69805772T2 (de) | Stabilisierte mischung auf fibrinogenbasis | |
DE60117984T2 (de) | Zusammensetzung und verfahren zur reparatur und regenerierung von knorpel und anderen geweben | |
EP0554570B1 (fr) | Procédé de production d'une solution stable de fibrinogène | |
EP0068047A2 (fr) | Dérivé enrichi du plasma pour favoriser la fermeture et la cicatrisation des plaies | |
CH646607A5 (de) | Haemostatisches mittel und verfahren zu seiner herstellung. | |
EP1393741A1 (fr) | Formulation du fibrinogene stable et liquid | |
DE19956503A1 (de) | Spritzbares Knochenersatzmaterial | |
EP1183043B1 (fr) | Medicament pour application locale, contenant du fibrinogene, de la thrombine, des transglutaminases et des inhibiteurs de protease | |
DE3225102A1 (de) | Gewebeklebstoff sowie verfahren zu dessen herstellung | |
EP1837039B1 (fr) | Adhésif tissulaire doté de propriétés anti-adhésives améliorées | |
EP1905460B1 (fr) | Matériau de remplacement osseux | |
DE69309685T2 (de) | Zweikomponenten-Fibrinkleber zur Verbesserung von in-Vitro Befruchtung | |
DE69425707T2 (de) | Medien für die isolierung und stabilisierung von zellen | |
WO1993015757A1 (fr) | Antidote pour l'hirudine et les inhibiteurs synthetiques de la thrombine | |
EP1528930B1 (fr) | Preparations pharmaceutiques de substances actives a capacite de production de thrombine et contenant de la thrombine et medicaments | |
EP1351697B1 (fr) | Agent pharmaceutique destine a favoriser la regeneration des tissus | |
AT407750B (de) | Verfahren zur herstellung einer vwf-präparation | |
EP0651659B1 (fr) | Composition de colle fibrine a deux composants servant a ameliorer la fertilisation in vitro | |
DE19529223A1 (de) | Verwendung von Plasminogenaktivatoren zum lokalen Knochenaufbau | |
AT407834B (de) | Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung | |
RU2383564C1 (ru) | Композиция - остеоиндуктор и остеокондуктор, при лечении костной патологии в стоматологии и челюстно-лицевой хирургии, и способ получения композиции - остеоиндуктора и остеокондуктора, при лечении костной патологии в стоматологии и челюстно-лицевой хирургии |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8331 | Complete revocation |